医疗保健中慢性肾脏病识别、监测和管理方面的性别差异:一项观察性队列研究
在斯德哥尔摩2009至2017年227,847名至少一次门诊eGFR<60 ml/min per 1.73 m²的成人中,女性获得CKD诊断编码、接受RASi和他汀、就诊肾内科及监测肌酐或白蛋白尿的几率均低于男性,且差异在调整合并症、白蛋白尿和教育程度后仍存在。
要点
- 女性获得CKD诊断的可能性低于男性(HR 0.43;95%CI 0.42至0.45)。
- 女性就诊肾内科的可能性低于男性(HR 0.46;95%CI 0.43至0.48)。
- 女性接受肌酐或白蛋白尿监测的可能性也低于男性。
核心结论
- CKD在检测、识别、监测、转诊和管理方面存在显著的性别差异,且在高风险人群和有指南推荐指征者中同样存在。
研究设计与样本
- 基于医疗保健的观察性队列研究,纳入斯德哥尔摩2009至2017年至少一次门诊eGFR<60 ml/min per 1.73 m²的成人227,847名,其中女性126,289名(55%)。
主要发现
- 纳入时,女性获得CKD诊断编码的比值比较低,且尽管有指南推荐指征,接受RASi和他汀的可能性也较低。
- 随访期间,女性获得CKD诊断的可能性较低(HR 0.43;95%CI 0.42至0.45),就诊肾内科的可能性也较低(HR 0.46;95%CI 0.43至0.48),与疾病严重程度、白蛋白尿或转诊标准无关。
- 女性接受肌酐或白蛋白尿监测的可能性也较低,包括糖尿病或高血压患者。
- 调整合并症、白蛋白尿和最高教育程度后,以及在重复检测确认CKD的受试者中,这些差异仍然存在。
- 尽管所有肾脏病照护指标随时间逐渐改善,但观察到的性别差距持续存在。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Reported sex differences in the etiology, population prevalence, progression rates, and health outcomes of people with CKD may be explained by differences in health care. METHODS: We evaluated sex as the variable of interest in a health care-based study of adults (n=227,847) with at least one outpatient eGFR<60 ml/min per 1.73 m2 measurement denoting probable CKD in Stockholm from 2009 to 2017. We calculated the odds ratios for diagnosis of CKD and provision of RASi and statins at inclusion, and hazard ratios for CKD diagnosis, visiting a nephrologist, or monitoring creatinine and albuminuria during follow-up. RESULTS: We identified 227,847 subjects, of whom 126,289 were women (55%). At inclusion, women had lower odds of having received a diagnostic code for CKD and were less likely to have received RASi and statins, despite having guideline-recommended indications. In time-to-event analyses, women were less likely to have received a CKD diagnosis (HR, 0.43; 95% CI, 0.42 to 0.45) and visited a nephrologist (HR, 0.46; 95% CI, 0.43 to 0.48) regardless of disease severity, presence of albuminuria, or criteria for referral. Women were also less likely to undergo monitoring of creatinine or albuminuria, including those with diabetes or hypertension. These differences remained after adjustment for comorbidities, albuminuria, and highest educational achievement, and among subjects with confirmed CKD at retesting. Although in absolute terms all nephrology-care indicators gradually improved over time, the observed sex gap persisted. CONCLUSIONS: There were profound sex differences in the detection, recognition, monitoring, referrals, and management of CKD. The disparity was also observed in people at high risk and among those who had guideline-recommended indications. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/JASN/2022_10_11_JASN2022030373.mp3.
引用
- Swartling O, Yang Y, Clase CM, et al. Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study. J Am Soc Nephrol. 2022. PMID: 35906075. doi:10.1681/ASN.2022030373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。